Alliance for Clinical Trials in Oncology

NIH launches precision medicine trial, myeloMATCH, to test new treatment combinations for AML and MDS, aiming to accelerate tailored treatments through rapid genetic testing and targeted drug combinations.

NIH's myeloMATCH trial tests precision medicine treatments for AML and MDS, aiming to accelerate tailored cancer therapies through genetic testing and targeted drug combinations.

MyeloMATCH, a precision-medicine initiative sponsored by the National Cancer Institute, aims to improve survival rates for acute myeloid leukemia and myelodysplastic syndrome through a coordinated, multisite clinical trial. Participants are screened for specific biomarkers and assigned to substudies targeting their genetic or molecular characteristics, with rapid diagnostic testing and potential for ongoing trial eligibility.

MyeloMATCH, a precision-medicine initiative, aims to improve survival rates for acute myeloid leukemia and myelodysplastic syndrome by conducting multiple clinical substudies based on genetic and molecular characteristics. It offers rapid diagnostic testing and is open to patients aged 18 and over, with ongoing substudies focusing on high-risk acute myeloid leukemia and FLT3 gene mutations. The initiative seeks to create a comprehensive pipeline for personalized treatment.

Final results from the CABINET phase III trial show cabozantinib significantly improves median progression-free survival in previously treated advanced neuroendocrine tumors, with no new safety concerns. The data was presented at ESMO 2024 and published in the New England Journal of Medicine.

Adjuvant pembrolizumab nearly doubles cancer-free time in high-risk, muscle-invasive bladder cancer patients post-surgery compared to observation, according to a large clinical trial published in the New England Journal of Medicine. The study found pembrolizumab effective regardless of PD-L1 status, with patients remaining cancer-free for a median of 29.6 months versus 14.2 months with observation. The trial, led by the National Institutes of Health, suggests pembrolizumab as an alternative to cisplatin-based chemotherapy for these patients.

Immunotherapy drug pembrolizumab nearly doubles cancer-free survival time in high-risk bladder cancer patients post-surgery, according to an NIH clinical trial published in the New England Journal of Medicine. Both PD-L1-positive and PD-L1-negative patients benefited, suggesting PD-L1 status should not dictate treatment eligibility.

The CABINET phase III trial showed cabozantinib significantly improved median progression-free survival (PFS) in previously treated neuroendocrine tumors (NETs), with 13.8 months for pNET and 8.4 months for epNET compared to 4.4 and 3.9 months for placebo, respectively. The results, presented at ESMO 2024 and published in NEJM, support cabozantinib as a potential new standard of care for advanced NET patients.

Final results from the CABINET phase III trial show cabozantinib significantly improves median progression-free survival (PFS) in previously treated advanced neuroendocrine tumors (pNET and epNET), with PFS of 13.8 months vs 4.4 months for pNET and 8.4 months vs 3.9 months for epNET. The study also demonstrated benefits across all clinical subgroups and a safety profile consistent with previous findings, leading to an early unblinding of the trial and a supplemental new drug application for cabozantinib.